UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hidradenitis suppurativa: Epidemiology and scope of the problem

Journal of the American Academy of Dermatology, 2015-11, Vol.73 (5), p.S4-S7

2015

Volltextzugriff (PDF)

Systemic associations of hidradenitis suppurativa

Journal of the American Academy of Dermatology, 2015-11, Vol.73 (5), p.S27-S35

2015

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology, 2017-03, Vol.76 (3), p.405-417

2017

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

Journal of the American Academy of Dermatology, 2008-06, Vol.58 (6), p.1031-1042

2008

Volltextzugriff (PDF)

Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

Journal of the American Academy of Dermatology, 2016-01, Vol.74 (1), p.190-192

2016

Volltextzugriff (PDF)

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.457-465

2010

Volltextzugriff (PDF)

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Journal of the American Academy of Dermatology, 2012-05, Vol.66 (5), p.742-751

2012

Volltextzugriff (PDF)

Risks of developing psychiatric disorders in pediatric patients with psoriasis

Journal of the American Academy of Dermatology, 2012-10, Vol.67 (4), p.651-657.e2

2012

Volltextzugriff (PDF)

Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis

Journal of the American Academy of Dermatology, 2017-06, Vol.76 (6), p.1198-1200.e1

2017

Volltextzugriff (PDF)

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2012-07, Vol.67 (1), p.76-85

2012

Volltextzugriff (PDF)

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results

Journal of the American Academy of Dermatology, 2015-01, Vol.72 (1), p.115-122

2015

Volltextzugriff (PDF)

Psoriasis and Cardiovascular Disease

The Medical clinics of North America, 2015-11, Vol.99 (6), p.1227-1242

2015

Volltextzugriff (PDF)

Counterpoint: Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States

Journal of the American Academy of Dermatology, 2013-11, Vol.69 (5), p.818-819

2013

Volltextzugriff (PDF)

Increased diagnosis of thin superficial spreading melanomas: A 20-year study

Journal of the American Academy of Dermatology, 2012-09, Vol.67 (3), p.387-394

2012

Volltextzugriff (PDF)

Placebo responders with moderate-to-severe hidradenitis suppurativa experience declines in inflammation as measured by C-reactive protein: a post hoc analysis of two double-blinded, randomized-controlled trials

International journal of women's dermatology, 2024-10, Vol.10 (3), p.e171-e171

2024

Volltextzugriff (PDF)

The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis

Journal of the American Academy of Dermatology, 2009-09, Vol.61 (3), p.405-410

2009

Volltextzugriff (PDF)

Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study

Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.525-526

2015

Volltextzugriff (PDF)

Genetic basis for skin youthfulness

Clinics in dermatology, 2019-07, Vol.37 (4), p.312-319

2019

Volltextzugriff (PDF)

Latitude and psoriasis prevalence

Journal of the American Academy of Dermatology, 2011-10, Vol.65 (4), p.870-873

2011

Volltextzugriff (PDF)

Data wobbles in hidradenitis suppurativa clinical trials and potential contributing factors: a retrospective review

International journal of women's dermatology, 2024-06, Vol.10 (2), p.e152-e152

2024

Volltextzugriff (PDF)

Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne

Journal of the American Academy of Dermatology, 2010-07, Vol.63 (1), p.52-62

2010

Volltextzugriff (PDF)

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

Journal of the American Academy of Dermatology, 2016-05, Vol.74 (5), p.851-861.e4

2016

Volltextzugriff (PDF)

Prednisone and amoxicillin/clavulanic acid for the treatment of hidradenitis suppurativa flares: a prospective observational study

International journal of women's dermatology, 2024-10, Vol.10 (3), p.e162-e162

2024

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(64)
Buchkapitel
(1)

Sprache

Englisch
(65)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(51)
Dermatology
(47)
Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Female
(29)
Male
(25)
Adult
(22)
Middle Aged
(18)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Psoriasis
(16)
Psoriasis - Drug Therapy
(16)
Psoriasis. Parapsoriasis. Lichen
(10)
Severity Of Illness Index
(10)
Quality Of Life
(8)
Treatment Outcome
(8)
United States
(8)
Antibodies, Monoclonal - Therapeutic Use
(7)
Psoriasis - Diagnosis
(7)
Young Adult
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Hidradenitis suppurativa: Epidemiology and scope of the problem

Systemic associations of hidradenitis suppurativa

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Risks of developing psychiatric disorders in pediatric patients with psoriasis

Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results

Psoriasis and Cardiovascular Disease

Counterpoint: Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States

Increased diagnosis of thin superficial spreading melanomas: A 20-year study

Placebo responders with moderate-to-severe hidradenitis suppurativa experience declines in inflammation as measured by C-reactive protein: a post hoc analysis of two double-blinded, randomized-controlled trials

The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis

Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study

Genetic basis for skin youthfulness

Latitude and psoriasis prevalence

Data wobbles in hidradenitis suppurativa clinical trials and potential contributing factors: a retrospective review

Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

Prednisone and amoxicillin/clavulanic acid for the treatment of hidradenitis suppurativa flares: a prospective observational study

Suchergebnisse filtern